The Interlinking Metabolic Association between Type 2 Diabetes Mellitus and Cancer: Molecular Mechanisms and Therapeutic Insights.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic links and therapeutic concepts without original data.
PubMed 39410536 · doi:10.3390/diagnostics14192132
What was done
This narrative review synthesized literature on the shared metabolic risk factors between type 2 diabetes mellitus and cancer, focusing on molecular mechanisms involving the PI3K/Akt/mTOR pathway and therapeutic implications of pathway inhibitors.
What was found
The abstract reports no quantitative data or numerical estimates. It describes that shared risk factors, particularly hyperinsulinemia, activate the PI3K/Akt/mTOR pathway to facilitate tumor proliferation, survival, metastasis, and anti-apoptosis, and notes that drug resistance limits single-agent pathway inhibitors, suggesting combination regimens.
Why it matters
It highlights how metabolic dysfunction in type 2 diabetes directly interacts with oncogenic signaling pathways, offering conceptual guidance for therapeutic targeting in patients with co-occurring cancer and diabetes.
Limits
As a narrative review, it presents no original empirical data, quantitative synthesis, or systematic search protocol. No specific sample sizes, effect sizes, or trial endpoints are reported in the abstract.
Cited by
- supports High sugar intake causes chronic hyperinsulinemia, which inhibits apoptosis in damaged or cancerous cells.